Author:
Fujiwara Ayana,Takemura Keisuke,Tanaka Anna,Matsumoto Misaki,Katsuyama Masato,Okanoue Takeshi,Yamaguchi Kanji,Itoh Yoshito,Iwata Kazumi,Amagase Kikuko,Umemura Atsushi
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542–1556. https://doi.org/10.1016/j.jhep.2023.06.003 (2023).
2. Harrison, S. A. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N. Engl. J. Med. 390, 497–509. https://doi.org/10.1056/NEJMoa2309000 (2024).
3. Umemura, A. et al. Potential therapeutic targets and promising agents for combating NAFLD. Biomedicines 10, 901. https://doi.org/10.3390/biomedicines10040901 (2022).
4. Wang, S. & Friedman, S. L. Hepatic fibrosis: A convergent response to liver injury that is reversible. J. Hepatol. 73, 210–211. https://doi.org/10.1016/j.jhep.2020.03.011 (2020).
5. Buniatian, G., Hamprecht, B. & Gebhardt, R. Glial fibrillary acidic protein as a marker of perisinusoidal stellate cells that can distinguish between the normal and myofibroblast-like phenotypes. Biol. Cell 87, 65–73 (1996).